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There is currently no cure for muscular dystrophies, although several
promising strategies are in basic and clinical research. One such strategy is
cell transplantation with satellite cells (or their myoblast progeny) to repair
damaged muscle and provide dystrophin protein with the aim of preventing
subsequent myofibre degeneration and repopulating the stem cell niche for
future use. The present review aims to cover recent advances in satellite
cell/myoblast therapy and to discuss the challenges that remain for it to
become a realistic therapy.
Introduction
Muscular dystrophies comprise a large group of heter-
ogeneous genetic disorders characterized by progres-
sive muscle weakness and degeneration, which vary
with respect to severity, the muscle groups affected
and the involvement of the heart [1]. Duchenne muscu-
lar dystrophy (DMD), the most severe form, is caused
by mutations in the gene for DMD, leading to a near
absence of functional dystrophin protein [2,3]. Dystro-
phin is located beneath the sarcolemma; it functions to
assemble the dystroglycan complex at the sarcolemma
and to connect the internal cytoplasmic actin filament
network and extracellular matrix, thus providing phys-
ical strength to the muscle fibre [4]. Myofibres lacking
dystrophin are easily damaged, leading to satellite cell-
mediated repair. However, the repaired/regenerated
myofibres in turn degenerate, leading to chronic mus-
cle degeneration and regeneration, as well as exhaus-
tion of the satellite cell pool. This results in the
eventual loss of muscle fibres and their replacement by
fibrotic and fatty tissue, compromising normal muscle
function [5].
Satellite cells are the principal skeletal muscle stem
cell. They reside between the sarcolemma and basal
lamina of muscle fibres and are mitotically quiescent
until required for growth or repair. Upon receiving
activation signals, they rapidly proliferate to produce a
pool of myoblasts that fuse with each other to form
nascent myofibres and/or with damaged fibres to
repair them. A small minority do not differentiate but,
instead, re-enter quiescence to maintain the stem cell
pool [6]. Satellite cells are extremely efficient at repair-
ing muscle; several thousand myonuclei can be gener-
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ated from a small number of transplanted satellite cells
contained on a single fibre [7] and even from just a
single satellite cell obtained by fluorescence activated
cell sorting [8]. Transplanted satellite cells can occupy
the satellite cell niche and participate in future rounds
of regeneration, indicating self-renewal and confirming
their stem cell status [7].
There is a body of experimental evidence to support
the hypothesis that not all satellite cells are function-
ally equivalent. Only a minority of satellite cells con-
tributes to muscle regeneration [7,8] and recent data
from satellite cell transplantation experiments have
suggested that there are two populations of satellite
cells. One population is responsible for myonuclei
addition during growth and general muscle mainte-
nance throughout life; these satellite cells are present
in greater numbers in growing muscle, are diminished
with age, and are more numerous in adult males com-
pared to females. The second population is formed by
those satellite cells that are activated by severe muscle
injury and survive transplantation; they are present in
similar numbers from birth to old age and do not dif-
fer between male and female mice [9]. A subpopulation
of satellite cells has been shown to produce distinct
daughter cell fates by asymmetrically segregating tem-
plate and newly-synthesized DNA strands [10]; these
may correspond to the ‘stem’ satellite cells that are
capable of contributing to muscle regeneration and
functionally reconstituting the satellite cell compart-
ment [7].
The findings that stem cells other than satellite cells
(derived from muscle, bone marrow, the interstitum or
the circulation) could also contribute to muscle regen-
eration led to studies moving away from using satellite
cells/myoblasts, towards atypical stem cells [11,12]. Of
the cells investigated, those with the greatest potential
appear to be mesoangioblasts [13,14], pericytes [15,16]
and CD133+ cells [17–19], as a result of their ability to
migrate through the vasculature (a major limitation of
satellite cell/myoblast therapy), to contribute to con-
siderable muscle regeneration and to engraft into the
satellite cell niche. Indeed, mesoangioblasts are cur-
rently being tested in a clinical trial for DMD, under
the direction of Guilo Cossu (Division of Regenerative
Medicine, San Raffaele Scientific Institute of Milan,
Italy). Other recently described but less well character-
ized cells, which may also hold some promise, are
PW1+ cells and amniotic fluid stem cells. PW1+ muscle
resident interstitial cells reportedly have a regenerative
capacity similar to satellite cells and can reconstitute
the satellite cell niche; however, so far, they have only
been isolated from mouse muscles and injected intra-
muscularly [20]. Amniotic fluid stem cells [21] are mul-
tipotent cells capable of undergoing myogenesis and
proof-of-concept studies have shown that they make
some contribution to muscle regeneration in mouse
models after local or systemic delivery [22,23]. The
recent discovery that, in the adult mouse at least,
Pax7+ satellite cells are the only cells that can regener-
ate skeletal muscle (i.e. their conditional genetic abla-
tion completely prevents regeneration [24–27]) suggests
that the myogenic contribution of other stem cells is
either negligible or requires paracrine factors released
by satellite cells for them to enter the myogenic pro-
gramme, or that ablation experiments result in exces-
sive disruption of muscle tissue, in turn perturbing the
homeostasis of other stem cells. This may help explain
the apparent discordant findings of Dellavalle et al.
[16], who elegantly demonstrated the fusion of muscle
resident pericytes with developing myofibres, as well as
pericytes, entering the satellite cell compartment during
postnatal growth. The re-establishment of the satellite
cell as the principal endogenous muscle stem cell
comes at a time when much effort is focused on cellu-
lar therapies. Recent advances in overcoming the limi-
tations of myoblasts, with the aim of improving their
regenerative capacity, are the focus of the present
review.
Myoblast cell therapy
Failure of early myoblast transplantation clinical
trials
Cell therapy (i.e. the delivery of myogenic cells to
enact muscle repair) has been considered as a potential
therapy for DMD for many years, ever since Partridge
et al. [28] demonstrated that donor myoblasts could
fuse with host myoblasts, suggesting the possibility of
functional restoration in defective fibres. The pivotal
discovery that donor heterologous myoblasts could
restore dystrophin expression in the dystrophin defi-
cient mdx mouse [29] set the precedent for a number
of human clinical trials in DMD patients in the 1990s
[30]. Disappointingly, little or no dystrophin restora-
tion was observed in the injected muscles and no func-
tional improvements were discerned [31–38]. The
failure of the trials was subsequently attributed to sev-
eral factors, including the rapid cell death of the
majority of cells within a few hours of transplantation,
the limited migratory capacity of transplanted cells
and a lack of immune suppression leading to graft
rejection [12]. It is also now known that myoblasts are
not as efficient as their parent satellite cells. Standard
culture greatly reduces their regenerative and self-
renewal capacity [39].
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Overcoming problems
Strategies to overcome some of these problems include
improved immunosuppression, the injection of more
cells but in smaller volumes to prevent ischaemic
necrosis, and high-density injection protocols to aid
migration [40]. Using these improvements, a recent
phase I clinical trial for DMD delivered a large num-
ber of allogeneic myoblasts using multiple injections
(high-density injection protocol) to the biceps brachii,
under continuous immunosuppression by tacrolimus
(FK506), to avoid rejection. Long-term expression of
donor-derived dystrophin was detected in 27.5% of
fibres 1 month after injection and, in 34.5% of fibres,
after 18 months [41,42]. Although promising, this was
only achieved in one patient, repair was localized to
the injection sites, long-term immunosuppression is
required and the protocol is only applicable to easily
accessible small muscle groups [43].
Clinical trials, using autologous myoblasts, for mus-
cular dystrophies that affect only subsets of muscles,
namely oculopharnygeal muscular dystrophy (Clinical-
Trial.gov identifier: NCT00773227) and facioscapu-
lohumeral muscular dystrophy (under the direction of
C. Desnuelle, Centre Hospitalier Universitaire de Nice,
France) are currently underway (initiated in 2005).
These have the benefit of not requiring immunosup-
pression. Oculopharnygeal muscular dystrophy is char-
acterized by late onset eyelid drooping (ptosis) and
dysphagia (difficulty swallowing) as a result of dystro-
phy of the pharyngeal muscle. Myoblasts from unaf-
fected limb muscles were grafted into the pharyngeal
muscle of patients, following on from promising pre-
clinical trials conducted in the beagle dog [44]. The
trial is a safety and efficacy trial, with results on any
swallowing improvements expected in 2015. A similar
trial using autologous myoblasts from non-affected
areas is underway for facioscapulohumeral muscular
dystrophy, which is characterized by asymmetric mus-
cle weakness, predominantly in the face, scapula and
upper arms. The results of this trial are expected soon.
However, it would not be possible to treat a muscular
dystrophy such as DMD with autologous myoblasts
because the regenerated myofibres would still lack dys-
trophin and therefore be prone to continuing bouts of
degeneration and regeneration. Because the use of
autologous cells may not require immunosuppression
of the patient, efforts have been made to genetically
modify autologous myoblasts. Vectors such as retrovi-
ruses and lentiviruses have been used to heritably
insert marker or therapeutic, genes into myoblasts;
however, retroviruses can only infect dividing cells,
and so the quiescent, more ‘stem-cell’ myoblasts would
not be transduced. Lentiviral vectors efficiently infect
quiescent cells, including stem cells [45], and, because
they integrate into the host genome, give long-term,
heritable, gene expression. The drawbacks of lentiviral
vectors include possible gene silencing, or mutagenesis
[46], as a result of the site at which the virus inserts
into the host genome. Although lentiviruses integrate
preferentially into active transcription sites [47], the
development of third-generation lentiviruses with an
advanced self-inactivating design, to reduce transacti-
vation of neighbouring genes [48], physiological pro-
moters (such as muscle creatine kinase or desmin) [49],
cell-specific envelope proteins [50] and enhancer-less
regulatory elements (e.g. the ubiquitously acting chro-
matin opening element) [49,51], should reduce the risk
of insertional mutagenesis or gene silencing.
A major disadvantage of lentiviruses is that they can
carry only a relatively small DNA insert of up to 10 kb
[52]. Lentiviral vectors have been used to insert either a
mini- or micro-dystrophin gene, or constructs designed
to skip mutated dystrophin exons, into myoblasts
[45,53,54]. These genetically-modified myoblasts con-
tribute to regenerated muscle fibres, containing a
shorter dystrophin protein, after their intramuscular
transplantation in animal models of DMD. Although
these engineered mini-dystrophins appear to retain most
of the functional properties of full-length dystrophin,
they nevertheless miss important domains, such as the
nitric oxide synthase-anchoring domain [55], and so an
important goal is to insert as large as possible func-
tional dystrophin construct into a lentiviral vector.
Improving myoblast culture
conditions
Why is it that myoblasts do not perform as well as
satellite cells? When placed in tissue culture, the major-
ity of satellite cells proliferate rapidly, although a
minority divide slowly and it is the latter that contrib-
ute more extensively to muscle regeneration in vivo
[56,57]. Selecting for a subpopulation of quiescent
myoblasts may improve their engraftment potential.
Small, nongranular mouse satellite cells [39] contribute
more effectively to muscle regeneration than larger,
granular satellite cells from the same preparations [58],
and sorting on the basis of satellite cell size and/or
specific cell surface markers [59] may be able to enrich
for the ‘stem’ satellite cells with enhanced muscle
regenerative capacity.
The ability to guide the behaviour and fate of stem
cells in culture is hindered by a limited understanding
of the niche composition and the regulation that it
imposes on satellite cell fate. The niche comprises both
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biochemical (e.g. growth factors, cytokines, receptor
ligands) and biophysical (matrix stiffness, topography,
fluidity, temperature, oxygen, pH) factors that direct
stem cell fate [60]. Modifying any of these factors can
have a pronounced impact on muscle regeneration and
satellite cell self-renewal.
It is now well recognized that oxygen tension is an
important component of stem cell niches. Most tissue
culture is performed using atmospheric levels of oxy-
gen (20%) when, in reality, tissue levels are much
lower, usually 2–9% (14.4–64.8 mmHg) depending on
the tissue; even within a tissue, there is considerable
variability depending on the proximity of cells to
blood vessels [61–64]. The neural stem cell niche has
an oxygen tension in the range < 1–8% oxygen, the
hematopoietic stem cell niche in the range 1–6% oxy-
gen and the mesenchymal stem cell niche in the range
2–8% oxygen [64], whereas the thymus, kidney
medulla and bone marrow can exist at 1% oxygen
[63]. Low oxygen levels are often referred to hypoxic
when, in reality, they are normoxic for the tissue or
cell in question. Culture in 20% oxygen can be toxic
to cells causing DNA damage and apoptosis [61],
whereas low levels of oxygen have been shown to pre-
vent oxidative stress caused by aerobic metabolism, in
turn preventing the generation of reactive oxygen spe-
cies that may cause DNA damage [61,64]. However,
for myoblast cultures, oxygen levels are routinely
uncontrolled [61,65].
Two recent studies highlight the benefits of using
more physiological levels of oxygen in the cultivation
of myoblasts. Duguez et al. [65] confirmed that atmo-
spheric oxygen is hyperoxic for myoblasts and
represses their proliferation, compared to myoblasts
cultured in 5% oxygen, and suggested that the mecha-
nism by which this occurs is via increased mitochon-
drial activation in hyperoxic conditions. We have also
observed a decreased proliferation of satellite cell-
derived myoblasts at 20% oxygen compared to 5%
oxygen (D. Briggs, L. Boldrin and J.E. Morgan,
unpublished results). Another study by Liu et al. [66]
demonstrated that reducing the oxygen level further
(to 1%) increases myoblast quiescence, reduces differ-
entiation and promotes self-renewal. It was elegantly
shown that hypoxia upregulates Pax7 through downre-
gulation of miR-1 and miR206, whose expression, in
turn, is controlled by the Notch signalling pathway
[66]. Furthermore, hypoxia conditioning was shown to
enhance the efficiency of myoblast transplantation and
self-renewal in vivo in cardiotoxin injured mdx mouse
muscles [66].
The importance of physiological tissue rigidity has
long been suspected but, as a result of the complexity
of reflecting this in vitro, has largely been ignored.
Using a bioengineering approach, Gilbert et al. [67] cre-
ated polyethylene glycol hydrogels, which mimic the
elasticity of muscle much more closely than standard,
rigid, tissue culture plastic. It was demonstrated that
soft substrates enhance satellite cell survival, prevent
differentiation and promote stemness (increased self-
renewal) in vitro and, more importantly, result in exten-
sive muscle regeneration in vivo compared to traditional
culture on plastic [67]. This was the first study to show
high levels of engraftment in mice from a small number
of transplanted cultured cells (100% incidence of
donor-derived engraftment was obtained from 1000
cells and 10% from just 10 cells), which represents an
efficiency comparable to the injection of 10 freshly-iso-
lated satellite cells [67]. The use of this artificial niche
will allow the influence that other biochemical niche
components have on stem cell fate and behaviour to be
examined at a single cell level, on a large scale, using
time-lapse microscopy and an algorithm that enables
automated analysis, garnering previously unobtainable
information [68]. Eventually, this should allow the
selection and subsequent expansion of the stem cell sub-
population of satellite cells (Fig. 1). Transplantation of
satellite stem cells rather than myoblasts would dramat-
ically improve donor-derived muscle regeneration.
Most satellite cell research is carried out using
mouse cells because only very low numbers of human
satellite cells can be obtained by muscle biopsy, which
are then cultured to increase the cell number and thus
become myoblasts. Recently, Latil et al. [69] showed
that satellite stem cells are enriched in post-mortem tis-
sue, adopting a dormant state and remaining viable
for up to 17 days in humans and 14 days in mice.
Obtaining satellite cells from post-mortem muscles
could provide a large number of human normal and
dystrophic satellite cells for research at the single cell
level and potentially could provide autologous satellite
cells for transplantation.
Modifying the environment
Satellite cells are absolutely necessary for muscle
regeneration [24–26,70]; however, they do not work
alone (Fig. 2). Regeneration is a multistep process
requiring resident and infiltrating immune and stromal
cells to remove debris, regulate satellite cell prolifera-
tion and differentiation, and allow muscle remodelling
[71,72]. The necessity of the inflammatory response has
been demonstrated in many studies, with a reduced
entry of monocytes/macrophages into injured muscle
causing a delay in regeneration and the persistence of
adipocytes [71–74]. Moreover, complete depletion
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strikingly results in no regenerative response, highlight-
ing the importance of inflammation [72,75].
Coinjection of pro-inflammatory (but not anti-inflam-
matory) macrophages, along with human myoblasts,
into regenerating muscle (injured by cryodamage) of
Rag2/cC/ immunodeficient mice improves donor-
derived muscle regeneration by extending the window
of proliferation, increasing migration and delaying dif-
ferentiation [76]. It is suggested that pro-inflammatory
macrophages can then switch to an anti-inflammatory
phenotype in vivo to stimulate differentiation of the
donor myoblasts [76]. These results provide the first
in vivo evidence for pro-inflammatory macrophages
having a supportive role in the regulation of myoblast
behaviour after engraftment into pre-injured muscle
[76]. A similar study, using the coinjection of mouse
macrophages and myoblasts, but into the dystrophic
environment of mdx mice, also reported improved
donor-derived regeneration, which was attributed to
improved donor myoblast survival, proliferation and
migration [77]. The increased survival was considered to
be a result of macrophages improving cell adhesion,
thereby decreasing ankiosis and having a mitogenic
effect by secreting growth factors. This is important in
the context of cell therapy because massive early cell
death, poor proliferation and migration are some of the
main obstacles that need to be overcome for it to
become a viable therapy option [77].
Another vital component of the regenerating niche is
muscle connective tissue (MCT) cells (stromal cells),
including fibroblasts and dual potential fibro/adipopro-
genitors (FAPs) [78]. Fibroblasts are necessary for
extracellular matrix and collagen synthesis and an
increase in extracellular matrix is a hallmark of regener-
ating muscle. The study of MCT fibroblasts had been
limited by the lack of specific markers until the recent
finding that MCT fibroblasts express the transcription
factor Tcf4 [79]. Using genetic ablation studies, Murphy
et al. [25] showed that Tcf4+ fibroblasts are required
for efficient regeneration, and that their loss leads to
premature satellite cell differentiation, depletion of the
myoblast pool and smaller regenerated fibres. Recipro-
cally, myoblasts promote MCT fibroblast proliferation
[25]. FAPs have only recently been described but repre-
sent a significant fraction of the mononuclear cells pres-
ent in muscle [80]. FAPs are quiescent in healthy
muscle but proliferate efficiently in response to damage;
their transient expansion during regeneration provides
Fig. 1. Potential protocol for improving cell therapy for muscular dystrophy. With advancements in the isolation and culture of muscle stem
cells, the following may become possible. Skeletal muscle satellite cells (SCs) could be obtained by muscle biopsy or from cadaver muscle
and enzymatically disaggregated to a single cell suspension containing an impure population of satellite cells. Satellite stem cells could be
purified by flow cytometry. Alternatively, satellite cells could be derived from reprogrammed iPSCs. Culture conditions that allow the
expansion of only the stem cell subpopulation of satellite cells would improve transplantation and require only limited cell numbers (e.g. the
use of hydrogels and low levels of oxygen). Genetic correction of autologous satellite cells would also be required. Preclinical studies in
animal models, such as the dystrophin deficient mdx mouse and golden retriever muscular dystrophy dog, would be performed to confirm
safety and efficacy before the therapy enters the clinic. Currently, satellite cells are only deliverable intramuscularly, although further
understanding of their biology may allow their modification so that they can be delivered systemically.
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signals that promote the terminal differentiation of pro-
liferating myoblasts [80]. A greater understanding of
this population of cells may lead to therapeutic strate-
gies for reducing the scarring and fibrosis found in dys-
trophic muscle, thereby providing an environment
amenable to muscle regeneration [80].
The effect of ageing on satellite cell function is a
matter of much debate because the loss of skeletal
muscle mass and function with increasing age (sarco-
penia) is of great importance in ageing western popula-
tions. However, despite evidence that the satellite cell
niche deteriorates with age [81] and that satellite cells
are lost with age [58,82], the regeneration-competent,
‘stem’ satellite cells are retained and those derived
from aged donors remain as functional as those from
young donors [9,58,83,84]. It therefore appears that
there are two subpopulations of satellite cell: one that
is lost with age and is responsible for maintaining
muscle mass, and a second that is retained throughout
life [9] and, given the correct environmental cues, can
contribute robustly to muscle regeneration.
Improving regeneration
There is a plethora of studies in mice examining ways
of augmenting the regenerative potential of myoblasts.
Preventing cell death, increasing proliferation and/or
migration, and decreasing early differentiation have all
been shown to have a positive impact on mouse and
human myoblast transplantations in immunodeficient
mice. For example, upregulating the heatshock
response (Hsp70 protein) improves both mouse and
human myoblast survival, leading to increased engraft-
ment [85,86]. Reducing hypoxia-related death by over-
expressing vascular endothelial growth factor has a
similar effect [87]. Overexpression of matrix metallo-
proteinase 9, a proteolytic enzyme that can remodel
the extracellular matrix, enhances myoblast migration
and engraftment [88]. Transforming growth factor-b
(TGF-b) is a negative regulator of skeletal muscle
development and elevated levels can limit skeletal mus-
cle regeneration [89]. Fakhfakh et al. [90] have shown
that treatment with oral losartan, a molecule that
downregulates TGF-b1 expression, improves the trans-
plantation efficiency of human myoblasts into immu-
nodeficient dystrophic mice, as demostrated by an
increase in dystrophin positive fibres 1 month after
engraftment compared to nontreated controls [90].
Increased myoblast survival was observed 3 days after
transplantation (10% versus 6% of radiolabelled cells),
which led to increased proliferation and differentiation
concomitant with the increased expression of Myf5,
MyoD and myogenin [90]. Blocking the myostatin sig-
nal (another negative regulator of muscle regeneration)
with a dominant negative receptor improves the suc-
cess of human myoblast transplantation by increasing
myoblast proliferation and fusion and changing the
expression of myogenic regulatory factors [91]. How-
ever, this approach may not be as straightforward as
hoped; a recent clinical trial using ACE-031 (a soluble
form of activin receptor type IIB, which binds to myo-
statin and other members of the TGFb family) in
Fig. 2. Schematic of satellite cell-mediated muscle regeneration. In
response to myofibre damage, satellite cells rapidly activate and
proliferate to produce a pool of myoblasts that fuse to repair or
replace damaged fibres. Infiltration by immune cells occurs,
including neutrophils, monocytes, pro-inflammatory and later anti-
inflammatory macrophages, along with stromal cells including
fibroblasts and FAPs secrete paracrine and autocrine factors,
remove debris and ensure efficient regeneration. The immune and
stromal cells do this by controlling the balance between myoblast
proliferation and differentiation and ensuring satellite cell self-
renewal to replenish the stem cell niche. A hallmark of regenerated
fibres in the mouse is the central (i.e. opposed to peripheral)
position of nuclei. IL-6, interleukin-6; TNFa, tumour necrosis
factor a.
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DMD patients, was terminated early because of safety
concerns (http://www.acceleronpharma.com/products/
ace-031/; ClinicalTrials.gov Identifier: NCT01099761).
Concerning the limited migratory capacity of human
myoblasts in vivo, several studies have linked this with
the limited proliferation of the injected myoblasts.
When human myoblasts are injected into the cryodam-
aged muscles of Rag2/cC/ immunodeficient mice,
in medium containing serum, which is rich in growth
factors, rather than NaCl/Pi, the window of prolifera-
tion is extended from 3 to 5 days. This increases migra-
tion, leading to enhanced regeneration as a direct result
of slower myoblast differentiation [92]. Similarly,
AG490 (a specific inhibitor of janus tyrosine kinase 2)
has been used to block myoblast differentiation, increas-
ing proliferation and cell survival in vivo [93]. However,
other studies have shown that, although co-injection of
insulin-like growth factor 1 and/or basic fibroblast
growth factor with human myoblasts improves myo-
blast migratory capacity and dispersal [94,95], growth
factor addition does not improve the transplantation
success in undamaged primate muscle [95], in contrast
to the enhanced regeneration observed in mice [92,96].
Challenges remaining
How to induce regeneration
A major problem with the intramuscular injection of
myoblasts in the human clinical trials was that regenera-
tion (dystrophin positive fibres) appeared to be limited
to damaged muscle along the injection trajectory. This
was also seen in primate experiments [40,95]. In mice,
successful engraftments require either pre-treatment of
the host muscle with irradiation [97,98], or an injury to
be administered to induce or increase muscle damage;
with use of the snake venom myotoxins notexin and car-
diotoxin [99] or cryodamage [100] being most common.
Irradiation limits the host satellite-cell contribution to
regeneration and provides an optimal environment for
donor mouse cell engraftment [84,98,101]. Cryodamage
destroys cells near to the injury site but preserves the
basal lamina of muscle fibres [102]. Following cryodam-
age, skeletal muscle can regenerate, indicating that at
least some satellite cells either survive the injury or
migrate into damaged areas [84]. Injection of myotoxins
destroys muscle fibres but preserves their basal lamina,
nerves, blood vessels and satellite cells [84]. Neither
cryodamage, nor myotoxins are as effective as irradia-
tion for enhancing mouse donor satellite cell-derived
muscle regeneration [84]. This is not the case for human
myoblasts, where cryodamage is at least as effective as
irradiation, allowing similar amounts of donor muscle
regeneration and engraftment of more total donor cells
(including cells outside of muscle fibres) [96,103]. The
reason for differences between the behaviour of mouse
and human myoblasts is not known, suggesting caution
with respect to the assumption that what works in mice
will also work in humans. For patients in whom it
would be unethical to use these pre-treatments, other
ways of increasing donor satellite cell or myoblast
engraftment might exist. Intense muscle exercise has
been shown to greatly improve myofibre regeneration in
mdx mice [104]. It is possible that exercise (rather than
an acute and extensive injury to the host muscle) may
be sufficient to promote donor-derived muscle regenera-
tion in patients.
Harnessing the potential of induced pluripotent
stem cells (iPSCs)
iPSCs [105] hold great promise for cell therapy; they
could potentially yield unlimited numbers of autolo-
gous stem/progenitor cells. This is important because
myoblasts, particularly dystrophic ones, undergo a lim-
ited numbers of doublings before entering senescence
and the use of donor heterologous myoblasts requires
life-long immunosuppression. A caveat is that patient-
derived iPSCs would still need to be genetically cor-
rected before transplantation. The generation and use
of human iPSCs does not pose the same ethical
dilemma as deriving human embryonic stem cells
(ESCs), making them a more attractive candidate
[106,107]. The technology for both ESCs and iPSCs is
limited by the efficiency of cell-lineage-specific differen-
tiation and the efficiency of cell purification to eliminate
the risk of teratoma, although many strategies are being
devised to overcome these limitations [108]. Repro-
gramming of mouse iPSCs and ESCs into satellite cells/
myoblasts has been achieved using various protocols
[109–111], although the equivalent reprogramming of
human iPSCs and ESCs has lagged behind. Only one
reported study, showing reprogramming of human
ESCs into myoblasts with limited efficiency [112], was
available until Darabi et al. [106], Tedesco et al. [113]
and Goudenege et al. [107] published new protocols for
deriving myogenic progenitors from iPSCs, based on
mesoderm commitment followed by myogenic tran-
scription factor overexpression, within a few months of
each other. Darabi et al. [106] and Goudenege et al.
[107] demonstrated very efficient reprogramming of
both human iPSCs and ESCs using the forced overex-
pression of different myogenic regulatory factors, spe-
cifically MyoD in an adenoviral vector [106] and Pax7
in a lentiviral vector [107]. Both methods gave highly
efficient myogenic conversion, with cells expressing high
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levels of the satellite cell marker CD56 and myosin
heavy chain upon in vitro differentiation, and notably
generating a large number of muscle fibres upon intra-
muscular transplantation into immunodeficient dystro-
phic mice [106,107] Darabi et al. [106] also
demonstrated a functional improvement in treated mus-
cles, long-term expression of donor-derived dystrophin
(11 months) and occupation of the satellite cell niche.
Tedesco et al. [113] used a similar strategy but went one
step further by deriving mesoangioblast-like cells (no
CD56 expression) from human iPSCs generated from
limb-girdle muscular dystrophy 2D (sub-type of limb-
girdle muscular dystrophy) patient fibroblasts or myo-
blasts. These cells were then lentivirally transduced with
both a therapeutic gene (Sgca, encoding a-sarcoglycan)
to correct the genetic defect and with MyoD to induce
myogenic differentiation. Importantly, donor cell
engraftment into Sgca-null immunodeficent mice, was
obtainable using both intramuscular and inter-arterial
injections, as indicated by a-sarcoglycan expression
[113]. However, there are safety concerns with iPSCs,
particularly the potential tumourigenicity of cells that
are not fully differentiated at the time of transplanta-
tion, as well as the genomic integrity of the iPSCs [114].
Concluding remarks
In recent years, there has been both an improved
understanding of the biology of satellite cells them-
selves, together with increasing knowledge on the
effect of the host skeletal muscle environment on their
function in vivo. In particular, the effect of factors
such as microRNAs, growth factors and extracellular
matrix components produced by host cells, including
myofibres, blood vessel-associated, stromal and inflam-
matory cells, and the effect of the host satellite cell
niche on donor satellite cell engraftment are particu-
larly relevant to improving donor cell engraftment. We
envisage that a combination of tissue culture condi-
tions to promote or retain the ‘stem-like’ myoblasts,
with modification of the host muscle environment to
enhance donor satellite cell migration, proliferation
and self-renewal, will be the way forward.
Because satellite cells and their progeny myoblasts
[15] do not appear to be systemically deliverable, they
could only be used to treat individual muscles,
although this might still be of benefit to patients with
DMD. If hand or finger muscles could be successfully
treated, this could improve the quality of life [115] by
allowing the patient, for example, to operate a com-
puter keyboard or touchscreen.
Even in the era of molecular therapies, myoblast or
other stem cell therapies are still highly relevant.
Although potential treatments for DMD such as exon
skipping are promising, exon skipping is neither appli-
cable to all DMD patients, nor will it restore lost
muscle fibres. An effective stem cell-based treatment
will therefore be a powerful alternative, or adjunct, to
other therapies.
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